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Australian bat lyssavirus (ABLV) is a rhabdovirus of the lyssavirus genus capable of causing fatal rabies-
like encephalitis in humans. There are two variants of ABLV, one circulating in pteropid fruit bats and
another in insectivorous bats. Three fatal human cases of ABLV infection have been reported with the
third case in 2013. Importantly, two equine cases also arose in 2013; the ﬁrst occurrence of ABLV in a
species other than bats or humans. We examined the host cell entry of ABLV, characterizing its tropism
and exploring its cross-species transmission potential using maxGFP-encoding recombinant vesicular
stomatitis viruses that express ABLV G glycoproteins. Results indicate that the ABLV receptor(s) is
conserved but not ubiquitous among mammalian cell lines and that the two ABLV variants can utilize
alternate receptors for entry. Proposed rabies virus receptors were not sufﬁcient to permit ABLV entry
into resistant cells, suggesting that ABLV utilizes an unknown alternative receptor(s).
Published by Elsevier Inc.Introduction
Until the discovery and isolation of Australian bat lyssavirus
(ABLV) from a black ﬂying fox (Pteropus alecto) in 1996, Australia
was considered free of endemic lyssaviruses, a group of globally
important zoonotic viral pathogens that continue to threaten
human health (Fraser et al., 1996). Capable of causing fatal acute
rabies-like encephalitis in humans, ABLV has since been a cause of
considerable concern to wildlife, veterinary, and health-care work-
ers. There are two genetically distinct variants of ABLV, one which
circulates in frugivorous bats (suborder Megachiroptera, genus
Pteropus (ABLVp)) and the other in the insectivorous yellow-
bellied sheathtail microbat (suborder Microchiroptera, genus
Saccolaimus) (ABLVs)) (Gould et al., 2002). While the prevalence
of ABLV in healthy bats is estimated to be less than 1%, in sick orInc.
r), ina.smith@csiro.au
ng@csiro.au (L.-F. Wang),injured bats it may be as high as 20% in ﬂying foxes, depending on
the species, and up to 62.5% in the yellow-bellied sheathtail bat
(Field, 2005). ABLV has caused three fatal human infections and
each manifested as acute encephalitis; however, incubation peri-
ods were variable. The ﬁrst fatal case occurred in November 1996
approximately 5 weeks after a 39-year-old female animal handler
was bitten presumably by a yellow-bellied sheathtail bat (Allworth
et al., 1996). A second fatal case was reported in November 1998,
more than 2 years after a 37-year-old female was bitten by a ﬂying
fox (Hanna et al., 2000). The most recent case occurred in an
8-year old boy in February 2013, when he began to suffer
convulsions, abdominal pain and fever, followed by progressive
brain problems and coma. He died approximately 8 weeks after he
was bitten (Anonymous, 2013a).
ABLV is a member of the family Rhabdoviridae, genus Lyssavirus.
The Lyssavirus genus is divided into 12 classiﬁed species (http://
www.ictvonline.org/virusTaxonomy.asp; accessed 02 May 2013) and
three recently described bat lyssaviruses not yet classiﬁed (Ceballos
et al., 2013); all species are capable of causing fatal neurological
disease indistinguishable from clinical rabies in humans and other
Fig. 1. Comparison of the amino acid sequences of Saccolaimus and Pteropus ABLV
G mature protein ectodomains. Scoring matrix: BLOSUM62.
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known bat reservoirs, leading to the speculation that lyssaviruses
originated in bats (Badrane and Tordo, 2001). Of the lyssavirus
species, ABLV is most closely related to classical rabies virus (RABV)
(Gould et al., 2002). Lyssaviruses are enveloped, bullet-shaped
viruses with a single-stranded, negative sense RNA genome that
encodes ﬁve viral proteins: nucleoprotein (N), phosphoprotein (P),
matrix (M), glycoprotein (G), and RNA polymerase (L). The G
proteins associate into trimers on the virion surface and mediate
viral attachment to and fusion with the host cell membrane (Gaudin
et al., 1992). Following host cell attachment, lyssaviruses are inter-
nalized by means of receptor-mediated endocytosis; the low pH of
the endosome triggers G-mediated fusion of the viral and host cell
membranes.
Studies aimed at identifying host factors required for lyssavirus
entry have thus far been limited to RABV. Lyssaviruses are highly
neurotropic in vivo, but can replicate at sites of inoculation such as
muscle tissue and epithelial cells (Burrage et al., 1985; Morimoto
et al., 1996) and do exhibit a broad in vitro tropism (Tuffereau et al.,
1998). For RABV, several host cell molecules have been proposed
as receptors, but none have been shown to be essential in vitro.
These include protein receptors such as nicotinic acetylcholine
receptor (nAChR) (Hanham et al., 1993; Lentz et al., 1982, 1984),
neuronal cell adhesion molecule (NCAM) (Thoulouze et al., 1998),
and p75 neurotrophin receptor (p75NTR) (Tuffereau et al., 1998),
as well as neuraminic acid containing glycolipids (gangliosides)
(Conti et al., 1986; Superti et al., 1986). The nAchR, predominantly
located in muscle cells, is not required for RABV infection of
neurons (McGehee and Role, 1995), but may account for replica-
tion of RABV in myotubes at the site of inoculation (Burrage et al.,
1985). The p75NTR does not interact with the majority of lyssa-
virus glycoproteins, including ABLV G (Tuffereau et al., 2001), and
is not essential for RABV infection (Tuffereau et al., 2007).
Similarly, although NCAM has been shown to be an in vitro
receptor for a ﬁxed strain of RABV, NCAM knock-out mice were
still susceptible to RABV infection, although the disease was
delayed by a few days (Thoulouze et al., 1998). The nature of the
ABLV receptor(s) has not been investigated.
In contrast to RABV which has both bat and terrestrial mammal
reservoirs, only bats are known reservoirs for ABLV. ABLV has been
isolated from ﬁve bat species including all four common species of
ﬂying fox present in mainland Australia (Pteropus alecto, P. polioce-
phalus, P. scapulatus and P. conspicullatus) and the insectivorous
microbat Saccolaimus ﬂaviventris; however, it is likely that all
Australian bats may potentially serve as host reservoirs of the virus
(Hooper et al., 1997; McCall et al., 2000). The ﬁrst ABLV spillover
into a terrestrial species other than humans was recently reported
in May of 2013, when two ill horses in Queensland tested positive
for ABLV infection and were euthanized, and presently the infec-
tions are presumably caused by exposure to infected microbats
(Anonymous, 2013b). The fatal human and recent equine infections
clearly demonstrate that ABLV can infect other non-bat species.
Furthermore, molecular evidence suggests that terrestrial RABV
evolved from bat lyssaviruses (Badrane and Tordo, 2001). Although
the risk of human exposure to ABLV is currently believed to be
limited to contact with infected bats, the establishment of ABLV in
terrestrial animal populations would signiﬁcantly increase this risk.
To understand the cross-species transmission potential of ABLV,
infection tropism should be better deﬁned. Characterization of ABLV
tropism will also provide important data for ABLV receptor
identiﬁcation.
In the present study, we developed ﬂuorescent protein-
encoding recombinant vesicular stomatitis viruses (rVSV) that
express ABLV G envelope glycoproteins and have used them to
examine ABLV entry and infectivity as a function of G. Target cell
lines derived from numerous mammalian species were permissiveto ABLV, indicating that the ABLV host cell receptor(s) is broadly
conserved. Notably, the two ABLV variants exhibited distinct
in vitro tropisms, suggesting that they can utilize alternate host
factors for entry. Also, cell lines resistant to ABLV G-mediated
infection were identiﬁed, and these also expressed proposed RABV
receptors, indicating that a receptor(s) required for ABLV host cell
entry remains to be identiﬁed.Results and discussion
In vitro tropism of ABLV-G mediated viral entry
The Saccolaimus and Pteropus ABLV variant G proteins are
highly homologous, sharing 92% amino acid identity within the
G ectodomain (Fig. 1). However, because a single amino acid
change within a viral glycoprotein can alter cellular tropism
(Tuffereau et al., 1989; Vahlenkamp et al., 1997), it is very possible
that ABLVs and ABLVp, which differ by 33 amino acids within the G
ectodomains, exhibit distinct tropisms. The very different incuba-
tion periods of human infections caused by the two variants, as
well as the lack of overlapping host reservoir species, also point to
possible tropism differences between ABLVs and ABLVp. To inves-
tigate ABLV tropism we developed and recovered maxGFP-
encoding replication competent recombinant vesicular stomatitis
viruses (rVSV) that express the G proteins from both ABLVs and
ABLVp and used them as infection screening tools to examine
infectivity and tropism, as a function of ABLV G. This approach has
several advantages over using WT ABLV. First, rVSV-ABLV G viruses
are safer and easier to manipulate than WT ABLV. Second, the
incorporation of GFP into the viral genome eliminates the need for
traditional ﬂuorescent antibody staining to detect infected cells.
Third, the inclusion of rVSV-VSV G as a positive control in all
infection assays enables us to distinguish between actual ABLV G
entry blocks and post-entry VSV inhibition. Previous studies that
examined in vitro RABV tropism and receptor usage did not control
for post-entry inhibition (Thoulouze et al., 1998; Tuffereau et al.,
1998). Furthermore, because the viral backbones of the rVSV
reporter viruses are identical except for the envelope glycopro-
teins, the tropism differences exhibited by the different viruses
can be attributed directly to differences among the G proteins
themselves.
Diverse target cell populations were infected with the rVSV-
maxGFP viruses at a multiplicity of infection (MOI) of 1 and the
percent of maxGFP positive cells, indicative of productive
Fig. 2. ABLV in vitro entry tropism. ((A)–(C)) Target cells infected with recombinant VSV-maxGFP reporter viruses at a MOI¼1 were harvested 18–20 h post infection and
ﬁxed with 2% paraformaldehyde. GFP expression, indicative of productive infection, was analyzed by ﬂow cytometry. The percent of virus-infected cells was calculated by
dividing the number of GFP positive cells by the total number of cells in the parent population. (A) Numerous mammalian cell lines are permissive to ABLV G-mediated host
cell entry. (B) Saccolaimus and Pteropus ABLV variants display unique in vitro entry tropisms. (C) Low ABLV infectivity of resistant cell lines is not due to post-entry VSV
inhibition. Data are the means from three independent experiments and error bars represent the standard error of the mean (SEM). Reporter viruses that express VSV G were
included as a positive control. N2a, mouse neuroblastoma; BHK, baby hamster kidney; 293T and 293F, human embryonic kidney; Vero, African green monkey kidney; CCRT,
cotton rat osteogenic sarcoma; HeLa USU, human cervical adenocarcinoma; CHO K1, Chinese hamster ovary; PCI-13, human head and neck sarcoma.
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Fig. 2A, several target cell lines derived from both neuronal and
non-neuronal tissues of numerous mammalian species, including
multiple species of small rodents, rabbit, human, monkey, and
horse, were permissive to viral entry mediated by the G proteins of
both ABLV variants. This is in agreement with the broad in vitro
tropism reported for RABV (Thoulouze et al., 1998). To date, except
for the three human infections and the two recent equine cases,
there have been no conﬁrmed reports of ABLV infection in other
terrestrial mammals despite known contacts of domestic dogs
with infected bats (McCall et al., 2005). Dogs and cats experimen-
tally infected with a laboratory adapted strain of ABLVp exhibited
mild behavioral changes and seroconverted within the 3 month
study, but none succumbed to ABLV and no viral antigen wasdetected at necropsy (McColl et al., 2007). However, this study was
only carried out for 3 months and it is possible that this was not
sufﬁcient time for the virus to reach the brain; the single
documented human ABLVp infection had an incubation period of
more than 2 years (Hanna et al., 2000). The ability of ABLVs to
cause clinical disease in dogs and cats has not been evaluated.
Nevertheless, the tropism data described here indicates that the
ABLV receptor(s) is highly conserved among mammals and sug-
gests that species other than bats, humans, and horses could
potentially be susceptible to ABLV infection.
Interestingly, we also identiﬁed three cell lines derived from
human (293F), insectivorous bat, and cat embryonic tissues that
exhibited a 6–45 fold difference in infectivity mediated by the G
proteins of ABLVs and ABLVp (Fig. 2B). All three cell lines were
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infected), but resistant to ABLVp G-mediated viral entry (o10%
total cells infected), suggesting that ABLV variants can utilize
alternate host factors for entry. It was surprising that the 293F
cells, which are a derivative of HEK293 cells that have been
adapted for growth in serum-free medium as suspension cells,
were resistant to ABLVp (o5% total cells infected) (Fig. 2B) given
that adherent 293T cells are highly permissive to both ABLV
variants (Fig. 2A). Dube et al. (2008) reported that 293F cells
grown as adherent, rather than suspension cultures were signiﬁ-
cantly more susceptible to Ebola virus envelope glycoprotein GP
pseudotyped virus infection. To determine whether a similar
phenomenon may exist for ABLVp G-mediated viral entry, 293F
cells were grown in serum-supplemented medium to allow the
cells to form adherent monolayers prior to infection with rVSV-
ABLV G reporter viruses. As shown in Fig. 3A, although 293F cells
grown in suspension were resistant to ABLVp G-mediated infec-
tion, cells grown as adherent monolayers were highly permissive
to infection; thus, it appeared that cell adhesion promoted ABLVp
infection. However, because adherent and suspension cultures of
293F cells were grown in the presence or absence of serum,
respectively, it was possible that it was the addition of serum,
rather than cell adhesion that promoted ABLVp infection of 293F
cells. To address this, 293T cells kept in suspension by continuous
rotation in microcentrifuge tubes were infected with rVSV-ABLVpFig. 3. Anti-clumping agents are potent inhibitors of entry mediated by Pteropus, but n
Fig. 2. (A) HEK 293F cells grown in Gibcos 293 SFMII serum-free medium (suspension
G-mediated infection. (B) Inhibition of ABLVp infection of suspension cultures of 293T i
microcentrifuge tubes were pelleted by centrifugation at 2000 g for 5 min. Cells were
medium as designated. (C) Proprietary Gibcos anti-clumping agent in 293 SFMII med
dextran sulfate (5 kDa) is a potent inhibitor of ABLVp G-mediated viral entry into 293 T
medium supplemented with three-fold dilutions of Gibcos anti-clumping agent beginn
sulfate (5 kDa) beginning with 200 mg/ml (D). Results are expressed as percent virus-inf
experiments and error bars represent SEM. nnnn, po0.0005; nnn, po0.005; nn, po0.01;G in the presence or absence of serum in several commercially
available media. Reporter virus that expressed VSV G was included
as a positive control. As shown in Fig. 3B, suspension cultures of
293T cells were highly permissive to ABLVp infection regardless of
whether serum was present (DMEM-10) or not (DMEM-0, Gibcos
293 Freestyle™, OptiMEMs); only cells cultured in Gibcos 293
SFMII medium, the standard culture medium used for 293F cell
maintenance, were resistant to ABLVp G-mediated viral infection.
VSV G-mediated infection was not inhibited, demonstrating that
the antiviral component within 293 SFMII medium blocks ABLVp
G-mediated infection at the level of entry.
Low molecular weight dextran sulfate is a potent inhibitor of viral
entry mediated by ABLVp G, but not ABLVs G
The complete formulations of 293 SFMII and OptiMEMs
serum-free media, which inhibits and supports ABLVp infection,
respectively, are not publicly available. However, the manufacturer
acknowledged that 293 SFMII medium contains a proprietary anti-
clumping reagent that is not present in OptiMEMs. To determine
whether the anti-clumping agent was responsible for the ABLVp
G-mediated viral inhibition, 293T cell culture medium was sup-
plemented with Gibcos anti-clumping agent prior to infection
with rVSV reporter viruses. As shown in Fig. 3C, the anti-clumping
agent signiﬁcantly inhibited ABLVp G-mediated infection in aot Saccolaimus ABLV G. ((A)–(D)) Cells were infected and analyzed as described in
cells), but not serum supplemented DMEM (adherent cells), are resistant to ABLVp
s restricted to cells grown in 293 SFMII medium. The 293T cells (5105) in 1.5 ml
washed once with PBS, pelleted, and then were resuspended in 500 ml of culture
ium inhibits ABLVp G-mediated entry into 293 T cells. (D) Low molecular weight
cells. The 293T monolayers were washed once with PBS prior to addition of culture
ing at 1:150 (C) or with two-fold serial dilutions of low molecular weight dextran
ected cells relative to that of untreated controls. Data represent three independent
n, po0.05.
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was signiﬁcantly reduced at the lowest dilution of anti-clumping
agent tested, only 20–30% inhibition was observed compared to
480% inhibition of ABLVp infection relative to untreated controls.
As expected, the agent had no effect on VSV G-mediated infection.
Low molecular weight dextran sulfate (5 kDa) is a conventional
anti-clumping agent that has been used by the manufacturer of
293 SFMII in past serum-free media formulations (Gorﬁen et al.,
2004). To determine whether dextran sulfate inhibited ABLVp
G-mediated viral infection, culture medium supplemented with
2-fold serial dilutions of 5 kDa molecular weight dextran sulfate
was added to 293T cell monolayers prior to infection with rVSV
reporter viruses. Results paralleled what was seen with the anti-
clumping agent: dextran sulfate reduced ABLVp G-mediated infec-
tion by up to 97% in a dose dependent manner (Fig. 3D). At the
highest dose, ABLVs G-mediated infection was signiﬁcantly inhib-
ited but the percent of inhibition was signiﬁcantly lower than that
observed for ABLVp at the same dose (20–30% versus 97%,
respectively). ABLVs was not inhibited at lower concentrations of
dextran sulfate and VSV was not inhibited at the concentrations
tested. Dextran sulfate has been reported to have antiviral activity
against numerous enveloped RNA and DNA viruses; the mechan-
ism of antiviral action is thought to be mediated by a direct
interaction of dextran sulfate with the viral envelope glycoproteins
(Witvrouw and De Clercq, 1997). In contrast to previous studies
which reported a potent antiviral effect of dextran sulfate on VSV
(Baba et al., 1988; Luscher-Mattli et al., 1993; Witvrouw and De
Clercq, 1997), in our experiments VSV entry was not inhibited at
any concentration of dextran sulfate tested (Fig. 3D). However, the
aforementioned studies used higher molecular weight dextran
sulfate and different cell lines, which may account for the different
experimental outcomes. The potent inhibition of ABLVp G-, but not
of ABLVs G-mediated viral entry by dextran sulfate strengthens the
argument that the two ABLV variants can exploit alternate recep-
tors to gain entry into host cells.
Low ABLV infectivity of resistant cell lines is not due to post-entry VSV
inhibition or lack of host cell attachment
Cell lines that were resistant to ABLV G-mediated infection,
with only 1–20% of total cells infected after 20 h, were also
identiﬁed in our in vitro tropism studies (Fig. 2C). These included
bovine kidney (MDBK), CHOK1, and a human head and neck
sarcoma cell line (PCI-13). VSV G expressing control viruses
infected greater than 80% of these cells, indicating that the
low ABLV infectivity was not due to post-entry VSV inhibition.
To examine whether the lower susceptibilities corresponded
to decreased viral binding, paraformaldehyde ﬁxed monolayers
of cells were incubated for 1 h at 37 1C with rVSV-ABLV viruses
(MOI¼20). Bound ABLV virus was detected by cell ELISA with anti-
ABLV G sera (see Materials and methods). BHK cells were included
as positive controls for viral binding. Although there was signiﬁ-
cantly (po0.01) less binding of ABLVs G to PCI-13 and MDBK cells
than BHK cells, ABLVs G was able to bind to all three resistant cell
lines and binding to CHOK1 was similar to permissive BHK cells
(Fig. 4A). Likewise, binding of ABLVp G to MDBK cells was
signiﬁcantly (po0.03) less than BHK cells; however, ABLVp G
bound to CHOK1, PCI-13, and BHK cells equally (Fig. 4B). Thus,
with the possible exception of ABLVp G-mediated infection of
MDBK cells, the decreased susceptibility of CHOK1, PCI-13, and
MDBK cells to ABLV G-mediated viral infection was not due to lack
of host cell attachment, suggesting that host cell entry of ABLV
may require interaction with two or more co-receptors. Dual- or
multi-receptor models have been proposed for a number of viruses
(Sieczkarski and Whittaker, 2005) as well as the highly neuro-
tropic botulinum and tetanus toxins (Popoff and Poulain, 2010).ABLV and rabies virus require alternate host factors for entry
The identiﬁcation of CHOK1 cells as an ABLV resistant cell line
was particularly interesting as these cells have been reported to be
highly permissive to the CVS-11 ﬁxed strain of RABV (Thoulouze
et al., 1998), suggesting that ABLV and RABV may utilize alternate
receptors for host cell entry. To conﬁrm this possible in vitro
tropism difference between ABLV and RABV, we rescued a recom-
binant VSV reporter virus that encodes the CVS-11 G protein and
tested the ability of this virus to mediate entry into ABLV resistant
CHOK1 and PCI-13 cells. BHK cells were included as a positive
control. CHOK1 and PCI-13 cells were highly permissive to VSV-
RABV CVS11 G infection, with 70–80% of total cells infected after
20 h (Fig. 5A). Expression of the proposed RABV protein receptors
nAchR (Fig. 5B) and NCAM (Fig. 5C) was conﬁrmed in both cell
lines. Although NCAM surface expression on CHOK1 cells was
approximately two-fold less than that on ABLV permissive BHK
cells, the CHOK1 NCAM levels were similar to those on mouse
neuroblastoma cells (N2a) (Fig. 5C), which are highly permissive to
both ABLV (Fig. 2A) and RABV infection (Thoulouze et al., 1998).
However, to verify that the low ABLV infectivity of CHOK1 cells
was not due to low expression of NCAM, a human NCAM (hNCAM)
cDNA clone was transfected into CHOK1 cells. Over-expression of
hNCAM was not sufﬁcient to allow ABLV G proteins to mediate
viral entry into transfected CHOK1 cells (Fig. 6A). This was not due
to lack of hNCAM expression in transfected cells (Fig. 6B). Further-
more, HeLa-USU cells, which do not express NCAM on the cell
surface (data not shown), are permissive to ABLV G-mediated
infection (Fig. 2A). Taken together, these results indicate that the
proposed RABV receptors nAchR and NCAM are not sufﬁcient to
allow host cell entry of ABLV. Rather, ABLV appears to utilize a
receptor(s) for host cell entry that has yet to be identiﬁed.
Disruption of lipid rafts signiﬁcantly reduces ABLV G-mediated viral
entry into 239T cells
The observation that proposed RABV receptors are not sufﬁ-
cient to allow ABLV G to mediate viral entry into host cells
prompted an examination of the nature of the unknown ABLV
receptor(s). We treated permissive target cells with increasing
doses of neuraminidase or protease (pronase, proteinase K, and
trypsin) and in no case was ABLV G-mediated entry inhibited (data
not shown). One possible explanation for these results could be
that ABLV G interacts with more than one host cell receptor for
entry, as is suggested by the ability of rVSV-ABLV G viruses to bind
to cells resistant to infection (Fig. 4). If the co-receptors belong to
different classes of macromolecules, as is the case for several
bacterial neurotoxins which utilize glycolipid and protein co-
receptors to enter neurons (Popoff and Poulain, 2010), then
treatment with protease or neuraminidase alone would not reduce
viral infection; surface bound virions would interact with func-
tional co-receptors as soon as the enzyme cleaved receptors were
recycled and replaced by native ones. Thus, protein or sialic acid
moieties as the ABLV receptor(s) cannot be ruled out.
We next examined whether lipid raft integrity was important
for ABLV G-mediated viral entry. To disrupt lipid rafts, 293T cell
monolayers were pre-treated with the cholesterol-sequestering
drug methyl-β-cyclodextrin (MβCD) for 1 h at 37 1C. The drug was
removed and the cells were washed extensively prior to rVSV
infection. Subsequent to depletion of cholesterol with MβCD,
culture medium was supplemented with menovalin (4 mg/ml) to
prevent de novo cholesterol synthesis. VSV reporter viruses
expressing VSV G, and Ebola virus GP (Ebo GP) were included as
negative and positive controls, respectively. As previously
reported, MβCD treatment caused a drastic reduction of Ebo
GP-mediated infection (Saeed et al., 2010) but enhanced VSV G-
Fig. 4. ABLV entry block in resistant cells is not due to lack of host cell attachment. (A) ABLVs G binding. (B) ABLVp G binding. Cell monolayers ﬁxed with 2% PFAwere blocked
with 3% BSA in PBS and incubated with rVSV virus (5106 IU) for 1 h at 37 1C. For detection of bound virus, cells were incubated overnight at 4 1C with either rabbit or
mouse anti-ABLVs Gs polyclonal serum (see Materials and methods), followed by incubation with HRP-conjugated secondary antibodies for 1 h at 37 1C. Reactions were
developed with ABTS substrate for 30 min at room temperature and absorbance was measured at 405 nm. The average value was calculated from duplicates. Background
absorbance, determined by incubation of target cells with primary and secondary antibodies only, was subtracted from plotted data. Data represent the mean of two
independent experiments and error bars represent SEM. BHK cells were included as a positive control. nn, po0.01; n, po0.03.
D.L. Weir et al. / Virology 444 (2013) 21–3026mediated infection (up to 40%) (Fig. 7) (Shah et al., 2006). ABLV
G-mediated infection was signiﬁcantly reduced (57% and 35%
inhibition for ABLVp and ABLVs, respectively) compared to
untreated controls (Fig. 7), suggesting that the ABLV receptor
(s) is localized or enriched in lipid rafts.Conclusions
In summary, we have developed replication-competent rVSV
maxGFP reporter viruses that encode ABLV G envelope glycopro-
teins and have used them to characterize ABLV entry tropism as a
function of G. The results presented here provide the ﬁrst in vitro
tropism data for a lyssavirus species other than classical RABV and
reveal that although ABLV and RABV are closely related and are
capable of causing identical fatal neurological disease in humans,
they display distinct in vitro tropisms and can utilize alternate host
receptors for viral entry. The same is true for Saccolaimus and
Pteropus variants of ABLV. The ABLV receptor(s) appears to be
highly conserved among mammalian species and may localize to
lipid rafts. A major obstacle to identifying speciﬁc host cell
receptors required for RABV entry has been the ability of ﬁxed
strains of RABV to replicate in most continuous cell lines
(Thoulouze et al., 1998; Tuffereau et al., 1998); thus, methods that
have been successfully used to identify receptors for other viruses
could not be used for RABV. Here however, we were able to
identify several cell lines resistant to ABLV G-mediated viral entry.
ABLV resistant CHOK1 cells in particular, which are easy to
transfect with expression plasmids, will be an invaluable tool for
future studies aimed at ABLV receptor identiﬁcation.Materials and methods
Cell lines and culture conditions
The following cell lines were obtained from the American Type
Culture Collection (ATCC): N2a (mouse neuroblastoma) (CCL-131);
BHK (CCL-10); RK-13 (rabbit) (CCL-37); Equus caballus (horse) (CCL-
57); Tadarida brasilliensis (bat) (CCL-88); MDBK (CCL-22); CHO-K1(CCL-61). 293T cells were provided by Gerald Quinnan (Uniformed
Services University). Cat embryo, HeLa-USU, PCI 13, and CCRT cell
lines have been described (Blanco et al., 2009; Bonaparte et al.,
2005; Bossart et al., 2001). Vero cells were provided by Alison
O'Brien (Uniformed Services University). 293F cells were purchased
from Invitrogen Corp (Carlsbad, CA). N2a, BHK, MDBK, CHO-K1,
293T, HeLa-USU, Vero, and CCRT cells were maintained in Dulbecco's
modiﬁed Eagle's medium (Quality Biologicals, Gaithersburg, MD)
supplemented with 10% cosmic calf serum (CCS) (Hyclone, Logan,
UT) and 2 mM L-glutamine (DMEM-10). PCI-13 cells were main-
tained in DMEM-10 supplemented with 10 mM HEPES (Quality
Biologicals). Rabbit and horse cells were maintained in Eagle's
minimal essential medium (EMEM) (Quality Biologicals) supple-
mented with10% CCS, 2 mM L-glutamine (EMEM-10) supplemented
with 1 mM sodium pyruvate. Bat cells were maintained in EMEM-10
supplemented with 0.85 g/l sodium bicarbonate. Cat embryo cells
were maintained in RPMI 1640 (Quality Biologicals) supplemented
with 10% CCS and 2 mM L-glutamine (RPMI-10). 293F cells were
maintained in 293SFMII (Invitrogen) supplemented with 2 mM L-
glutamine. All cell cultures were maintained at 37 1C in a humidiﬁed
5% CO2 atmosphere.
Reagents and antibodies
OptiMEMs culture medium, Gibcos Freestyle™ 293 expres-
sion medium, and Gibcos anti-clumping agent were purchased
from Invitrogen. Dextran sulfate sodium salt (5 kDa) methyl-β-
cyclodextrin (MβCD) and mevinolin were purchased from Sigma
(St. Louis, MO). Stock solutions were prepared in water (dextran
sulfate and MβCD) or DMSO (mevinolin) and stored, as per
manufacturer's recommendation. Polyclonal rabbit and mouse
anti-sera against ABLV G were produced in mice and rabbits
(Spring Valley Laboratories, Sykesville, MD). Goat anti-rabbit and
anti-mouse IgG (H+L) horse radish peroxidase (HRP) conjugated
secondary antibodies were purchased from Pierce, Rockford, IL).
Mouse MAbs speciﬁc for mouse (catalog no. 60211A) and human
(catalog no. 559043) neural cell adhesion molecule (NCAM) were
purchased from BD Biosciences, San Jose, CA. Rabbit anti-nicotinic
acetylcholine receptor alpha 4 polyclonal antibody [N1C1] (catalog
no. GTX113653) was purchased from GeneTex Inc., Irvine, CA.
Fig. 5. ABLV resistant cells express proposed rabies virus receptors. (A) ABLV
resistant cell lines are highly permissive to rabies virus G-mediated viral entry.
Cells were infected as described in Fig. 2. GFP positive cells were counted with a
Nexcelom Vision automated cell counter with ﬂuorescence detection and the
percent of virus-infected cells was calculated by dividing the number of GFP
positive cells by the total number of cells counted. Data represent the mean of two
independent experiments and error bars represent SEM. (B) Endogenous nicotinic
acetylcholine receptor (nAchR) expression. Cell lysates were prepared in buffer
containing Triton X-100, clariﬁed by centrifugation and analyzed by 4–12% BT SDS
PAGE. An equivalent of 1106 cells per well were analyzed as described in the
methods. nAchR was detected by Western blotting with rabbit anti-nAchR alpha
4 polyclonal antibody. BHK cells were included as a positive control.
(C) Endogenous surface expression of neural cell adhesion molecule (NCAM). Cell
monolayers ﬁxed with 2% PFA were blocked with 3% BSA in PBS and then incubated
overnight at 4 1C with mouse anti-NCAM mAbs (3 mg/ml) speciﬁc for mouse (BHK,
N2a and CHOK1) or human (PCI-13) NCAM. Following incubation with HRP
conjugated anti-mouse IgG for 1 h at 37 1C, reactions were developed with ABTS
substrate for 30 min at room temperature. Absorbance was measured at 405 nm
and the average value was calculated from duplicates. Incubation of target cells
with secondary antibody only was used to determine background absorbance and
was subtracted from plotted data. Data represent at least two independent
experiments and error bars represent SEM. BHK and N2a cells were included as a
positive control.
D.L. Weir et al. / Virology 444 (2013) 21–30 27Plasmids
Full-length ABLV G cDNA sequences for both the Pteropus (ABLVpG)
(GenBank accession AF426309.1) and Saccolaimus (ABLVs G)(GenBank accession AAN63540.1) variants (Guyatt et al., 2003)
were codon optimized and synthesized by Geneart Inc., Germany
and then cloned into the mammalian expression vector pCAGGS
(Niwa et al., 1991). The Rabies virus strain CVS-11 G sequence
(GenBank accession EU352767.1) was synthesized by GenScript USA
Inc., Piscataway NJ, and then cloned into a promoter-modiﬁed
pcDNA3.1 vector. Plasmids that encode the vesicular stomatitis
virus (VSV) nucleoprotein (N), phosphoprotein (P), and RNA poly-
merase (L) genes and a full-length anti-genomic VSV Indiana cDNA
clone that expresses Ebola Zaire virus glycoprotein GP and the
ﬂuorescent mCherry protein were kindly provided by Paul Bates
(University of Pennsylvania). Recombinant VSV reporter plasmids
that express maxGFP (Lonza Inc., Allendale, NJ) were constructed by
replacing the mCherry gene, in the full-length anti-genomic VSV
Indiana cDNA clone, with that for maxGFP. To construct full-length
VSV-ABLV G-reporter plasmids, standard cloning techniques were
used to replace the Ebola GP gene with ABLVs G and ABLVp G genes.
VSV-GFP reporter plasmids that express Rabies CVS11 G and native
VSV G (Indiana) were similarly constructed. All VSV-GFP reporter
plasmids were then used to rescue replication competent recombi-
nant VSV reporter viruses. An open reading frame (ORF) clone of the
human neural cell adhesion molecule 1 (phNCAM1), transcript
variant 2 (catalog no. RC207890) was purchased from OriGene
Technologies, Inc., Rockville, MD.
Recovery, puriﬁcation and titration of rVSV
Recombinant reporter viruses were recovered using reverse
genetics (Lawson et al., 1995) with some modiﬁcations. HEK293T
cells grown to 70–80% conﬂuence in 6-well culture plates were
transfected with plasmids encoding the recombinant VSV anti-
genomic RNA (2.5 mg) and the VSV N (2.5 mg), P (2.5 mg), and
L (0.5 mg) genes under control of the bacteriophage T7 promoter
using the Lipofectamine LTX transfection reagent. After 4–5 h, the
transfection mix was removed and cells were infected with MVA-
T7 (Sutter et al., 1995) at a multiplicity of infection of 1. After 1 h,
the viral inoculum was removed, cells were washed three times
with PBS, and fresh medium was added to the wells. After 48 h
incubation at 37 1C, cells and supernatants were collected and
subjected to three rounds of freeze-thawing (−80 1C, 37 1C) to
release cell-associated virus. Cell debris was pelleted from the
lysates by centrifugation for 5 min at 1300 g. The clariﬁed lysate
was slowly ﬁltered through a 0.22 mm ﬁlter to remove the MVA-T7.
Five hundred microliters of the lysate was then added to ∼2106
293T cells on a 6-well plate in 1.5 ml of DMEM-10. After 48 h, cells
were observed for ﬂuorescent reporter gene expression and CPE
by microscopy (10 objective).
To prepare viral stocks, 293T cells in T-162 ﬂasks were infected
with the rVSV virus and supernatants were collected 24–48 h later.
Cell debris was removed by centrifugation at 2600 rpm for 10 min.
Clariﬁed supernatant was layered on top of 20% sucrose in TNE
buffer (10 mM Tris, 135 mM NaCl, 2 mM EDTA) and centrifuged at
27,000 rpm for 2 h. Virus pellets were resuspended in 10% sucrose/
TNE buffer. Viral titers were determined by adding serial 10-fold
dilutions of virus to 293T cells grown on 96-well plates. At 24 h
post-infection, ﬂuorescent cells were counted under a ﬂuorescent
microscope and calculated as infectious units/ml (IU/ml).
Cell infection assays
Target cells were infected with rVSV-GFP virus at a MOI¼1.
18–20 h post-infection, cells were harvested and ﬁxed with
2% paraformaldehyde (PFA). GFP expression, indicative of produc-
tive infection, was analyzed by either ﬂow cytometry or a
Nexcelom Vision cellometer (Nexcelom Bioscience LLC., Lawrence,
MA) capable of ﬂuorescence detection. The percent of infected
Fig. 6. The rabies virus receptor neural cell adhesion molecule (NCAM) is not a receptor for ABLV. (A) Over-expression of human NCAM1 (hNCAM1) does not render CHOK1
cells permissive to ABLV. CHOK1 cells transfected with an hNCAM1 cDNA clone (see Materials and methods) were infected 24 h post-transfection and analyzed as described
in Fig. 5A. Results shown are the mean from two independent experiments and error bars represent standard error of the mean. (B) Human NCAM1 surface expression in
hNCAM-transfected CHOK1 cells. Mock and hNCAM -transfected cells were ﬁxed with 2% paraformaldehyde 24 h post-transfection. A mouse anti-human NCAM mAb was
used to detect NCAM expression by cell ELISA as described in Materials and methods.
Fig. 7. Disruption of lipid rafts signiﬁcantly reduces ABLV G-mediated viral entry
into 293T cells. The 293T cell monolayers were treated with methyl-β-cyclodextrin
(MβCD) diluted in OptiMEM for 1 h at 37 1C. The drug was removed and the cells
were washed three times with PBS to remove the drug. Cells were infected with
rVSV (MOI¼1) diluted in OptiMEM supplemented with 4 mg/ml mevinolin and
analyzed as described in Fig. 5A. rVSV viruses encoding Ebo GP and VSV G were
used as positive and negative controls, respectively, to assess MβCD activity. Results
are expressed as percent virus-infected cells relative to that of untreated controls
and represent three independent experiments; error bars are SEM. nn, po0.01; n,
po0.05.
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by the total number of cells in the parent population and multi-
plying by 100. To determine the effect of anti-clumping agents on
ABLV G-mediated infection, cells were treated with Gibcos anti-
clumping agent (3-fold dilutions beginning at 1:150) or low
molecular weight dextran sulfate (5 kDa) (2-fold dilutions begin-
ning at 200 ug/ml) diluted in OptiMEM serum free medium
(Invitrogen). To determine whether cholesterol enriched lipid raft
domains are important for ABLV entry, 293T cell monolayers were
treated with the cholesterol sequestering drug methyl-β-
cyclodextrin (MβCD) diluted in OptiMEM for 1 h at 37 1C. Cells
were then washed three times with PBS to remove the drug and
infected with rVSV (MOI¼1) diluted in OptiMEM supplemented
with 4 mg/ml mevinolin to prevent de novo synthesis of choles-
terol. Pilot experiments indicated that 10 mM MβCD appeared
toxic and cells detached from the culture plates; cells treated with
5 mM MβCD initially looked healthy, but cell viability was drasti-
cally reduced by the end of the experiment. In the ﬁnal experi-
ments 2.5 mM MβCD was used. To assess MβCD activity, rVSV
viruses encoding Ebo GP and VSV G were used as positive and
negative controls, respectively. In all drug treatment experiments,
results are expressed as percent virus-infected cells relative to that
of untreated controls
Virus binding assay
Target cells (2105) grown in 8-well chamber slides were
washed once with cold PBS, and then ﬁxed with 2% PFA for 30 min
at room temperature. Fixed cell monolayers were blocked with 3%
bovine serum albumin in PBS (BSA/PBS) for 1 h at 37 1C and then
incubated with rVSV virus (5106 IU) diluted in 200 ml BSA/PBS
for 1 h at 37 1C. After washing with PBS (3X) cells were incubated
overnight at 4 1C with rabbit anti-ABLVs Gs polyclonal serum
(1:10,000) to detect bound VSV-ABLVs G virus or with mouse
anti-ABLVs Gs polyclonal serum (1:2000) to detect bound VSV-
ABLVp G virus. Cells were washed with PBS (3X) and then
incubated 1 h at 37 1C with either goat anti-rabbit IgG or goat
anti-mouse IgG HRP conjugated antibodies (1:10,000) diluted in
200 ml BSA/PBS. After three washes with PBS, cells were incubated
with 200 ml of ABTS [2-'2′-azino-di- (3-ethylbenzthiazolinesulfonic
acid)] substrate (Roche, Indianapolis, IN) for 30 min at room
temperature. The developed substrate (100 ml) was transferred toa 96 well plate and absorbance was measured for each well at
405 nm, and the average value was calculated from duplicates.
Target cells incubated with primary and secondary antibodies in
the absence of virus were used as background controls.
Western blot analysis
Cell lysates were prepared by treatment of 5106 cells of each
population with lysis buffer (100 mM Tris-HCl (pH 8.0), 100 mM
NaCl, 0.5% Triton X-100, 1X complete protease inhibitor cocktail
(Roche)). Lysates were clariﬁed by centrifugation at 13,200 rpm for
10 min at 4 1C and 20 ml of prepared lysate were loaded per well
(an equivalent of 1106 cells/well) and analyzed by 4–12% Bis-Tris
SDS PAGE (Invitrogen) under reducing conditions (2% β-
mercaptoethanol in NuPAGE sample buffer). Following transfer
to nitrocellulose paper, the blot was probed with rabbit anti-
nicotinic acetylcholine receptor alpha 4 polyclonal antibody
(1:1000), followed by incubation with HRP-conjugated goat anti-
rabbit IgG (1:20,000).
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Cell monolayers grown in 24-well plates were washed once
with cold PBS, and then ﬁxed with 2% PFA for 30 min at room
temperature. Fixed cell monolayers were blocked with 3% bovine
serum albumin in PBS (BSA/PBS) for at least 1 h at 37 1C and then
incubated overnight at 4 1C with mouse anti-NCAM mAbs (3 mg/
ml) diluted in 250 ml BSA/PBS. Cells were washed three times with
PBS and then incubated 1 h at 37 1C with HRP-conjugated goat
anti-mouse IgG (1:10,000) diluted in 250 ml BSA/PBS. After three
washes with PBS, cells were incubated with 300 ml of ABTS
substrate for 30 min at room temperature. The developed sub-
strate (100 ml) was transferred to a 96 well plate and absorbance
was measured for each well at 405 nm, and the average value was
calculated from duplicates. Target cells incubated with secondary
antibody alone were used as background controls.
Expression of human NCAM1 in CHOK1 cells
CHOK1 cells were grown overnight to 60–80% conﬂuence in 24
well culture plates. Cells were transfected with 0.5 mg of phNCAM1
plasmid or empty vector (mock) (eight wells each) using the
Lipofectamine LTX transfection reagent (Invitrogen) according to
the manufacturer's protocol. Twenty four hours post-transfection,
cells were infected in duplicate with rVSV virus and analyzed as
described above. Expression of hNCAM1 was assessed 24 h post
transfection by cell ELISA.
Statistical analysis
Student's t-test was used to evaluate the statistical signiﬁcance
levels of the data, with po0.05 indicating statistical signiﬁcance.Acknowledgments
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